Institutional Analyst: Our #1 Internet Company, Society Pass (Nasdaq: SOPA), Holds Appeal for Both...

Press Release: February 28, 2023 07:30 ET | Source: Society Pass Incorporated New York,...

LQR House (LQR) Commits to Postpone Public Offerings for the Foreseeable Future.

LQR House Initiates Warrants Cancellation and Commits to Postpone Public Offerings for the Foreseeable Future

Continued Strength at LQR House (LQR) Post-Reverse Split.

Like a Surprise Christmas Gift, LQR House has Gained Nearly Four-Fold (330%) Post Split. New Report out Tomorrow.

LQR House (LQR) +65%, Rebounding On New Clients Announcements.

The Liquor House Continues to Impress. We called this the most interesting Company of 2023. While extreme volume...

Jose Manuel Calderon Joins Hapbee (HAPB).

Prominent athlete participates in Private Placement and will contribute to Hapbee's expansion in global sports.

Thumzup Media (TZUP) Ascends to Top 6.3% of All Active Reg A+ and Reg...

$1 Million Get's You in Top 10% of all Reg A's and Reg CF's? LIVE QUOTE

Report: Expedia, Doordash, eCommerce Fashion Retailer and YouTube All Rolled Into One?

Society Pass (SOPA) has Acquired and is Operating in Six Verticals, With More to Come. Society Pass currently has...

Is Smart for Life (SMFL) $4.30, a Bargain Post Reverse Split?

We Think Yes..! With the year just finished ringing in $17.8 million in revenues, versus a market capitalization of...

Maxim Group Targets 175% Gain in Society Pass (SOPA) to $2.75.

If we average out the two most recent price targets this month, we come out with a potential gain of 337% and...

Report: Think Equity Updates Society Pass (SOPA). $6.00 Price Target.

Think Equity: Society Pass (Nasdaq: SOPA) – Path to Profitability NEW YORK, NY, March 14, 2023 (GLOBE NEWSWIRE) --...

Latest article

Institutional Analyst Newsletter. Citius (CTXR), GeoVax (GOVX.

DERBY WEEKEND - WE'RE HEADED TO TAMPA!HAT'S ON, DRINK'S UPADDING CITIUS PHARMA (CTXR) $0.66, TO WATCHLISTUPDATING GEOVAX LABS (GOVX) $1.43OUR $26...

Adding Citius Pharma (CTXR) $0.66 to 2024 Watch List.

Three Years Since we Last Added Citius (CTXR) to the Watch List, and it Looks Better Than Ever!

Citius Pharmaceuticals (CTXR) Prospectus, Powerpoint & Fact Sheet.

CRANFORD, N.J., April 26, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization...